BLBenshang Li

Benshang Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Benshang Li has a total of 91 co-authors. Here are the top co-authors by number of shared publications:

  • Chengjuan Luo

    Department of Hematology/Oncology, National Health Committee Key Laboratory of Pediatric Hematology & Oncology, Shanghai Children’s Medical Center, Shanghai Jiao Tong University School of Medicine

    7 shared publications
  • Xiang Wang

    Department of Hematology/Oncology, National Health Committee Key Laboratory of Pediatric Hematology & Oncology, Shanghai Children’s Medical Center, Shanghai Jiao Tong University School of Medicine

    7 shared publications
  • Yanjing Tang

    Department of Hematology/Oncology, National Health Committee Key Laboratory of Pediatric Hematology & Oncology, Shanghai Children’s Medical Center, Shanghai Jiao Tong University School of Medicine

    7 shared publications
  • Jing Chen

    Department of Hematology/Oncology, National Health Committee Key Laboratory of Pediatric Hematology & Oncology, Shanghai Children’s Medical Center, Shanghai Jiao Tong University School of Medicine

    6 shared publications
  • Tianyi Wang

    Department of Hematology/Oncology, National Health Committee Key Laboratory of Pediatric Hematology & Oncology, Shanghai Children’s Medical Center, Shanghai Jiao Tong University School of Medicine

    6 shared publications
  • Xinyu Wan

    Department of Hematology/Oncology, National Health Committee Key Laboratory of Pediatric Hematology & Oncology, Shanghai Children’s Medical Center, Shanghai Jiao Tong University School of Medicine

    6 shared publications

Latest Publications

  • Anti-CD19/CD22 CAR T cells in refractory immune thrombocytopenia of paediatric systemic lupus erythematosus

    by Chen-Xing Zhang, Jing Zhang, Jia He, You-Ying Mao, Jia-Yao Shen, Wei Zhou, Kang An, Meng Su, Juan Qian, Yan-Jing Tang, et al.

  • Open Access

    Long-term outcomes of co-administration of CD19 and CD22 CAR-T cell therapy in pediatric patients with relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia

    by Zichao Zhou, Tianyi Wang, Wenhua Shi, Xinyu Wan, Wenjie Li, Yue Li, Jing Yang, Xiaomin Yang, Liu Yang, Jing Zhang, et al.

    Background: Despite initial responses, resistance to tyrosine kinase inhibitors (TKIs) and disease relapse remain major challenges in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL). Given the efficacy of chimeric antigen receptor T (CAR-T) cell therapy in Relapsed/Refractory (R/R) ALL, we aimed to evaluate the long-term outcomes of co-administration of CD19 and CD22 CAR-T cell therapy for pediatric patients with R/R Ph + ALL. Methods: We conducted a retrospective subanalysis of patients with R/R Ph + ALL to assess the long-term outcomes of co-administration of CD19 and CD22 CAR-T cell therapy. Complete hematologic remission (CHR), measurable residual disease-negative complete remission (MRD − CR), complete molecular remission (CMR), relapse-free survival (RFS), and overall survival (OS) were among the important outcomes that were evaluated with a data cutoff of October 1, 2025. Results: Within 1 month after CAR-T cell infusion, all patients achieved CHR, with MRD − CR and CMR of 100 and 77.8%, respectively. Two patients underwent consolidative allogeneic stem cell transplant (allo-HSCT). Notably, six patients achieved sustained CHR without allo-HSCT. At a median follow-up of 54.93 months (range, 16.83–71.6 months), the 4-year OS and RFS were 91.7 and 66.7%. No treatment-related deaths occurred from CAR-T toxicity. Conclusion: These preliminary findings suggest that CD19 and CD22 CAR-T cell therapy may provide long-term survival benefits in pediatric patients with R/R Ph + ALL, with manageable toxicity. However, these results should be considered hypothesis-generating and require validation in larger, controlled studies. Clinical Trial Registration: https://www.chictr.org.cn/showproj.html?proj=52403 , ChiCTR2000032211.

  • Open Access

    CD19/CD22-targeted CAR T cells in autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation

    by Liu Yang, Xinyu Wan, Chengjuan Luo, Xiaohang Huang, Meng Su, Xia Qin, Jing Zhang, Kang An, Juan Qian, Tianyi Wang, et al.


  • Open Access

    Bicistronic-CD19/22 Chimeric Antigen Receptor T-Cell Therapy for Childhood Refractory Lupus Nephritis

    by Youying Mao, Weidong Shen, Jiayao Shen, Chenxing Zhang, Kang An, Yanjing Tang, Juan Qian, Benshang Li, Lei Yin


  • Open Access

    GREM1 deficiency induced bone marrow adipose niche promotes B‐cell acute lymphoblastic leukemia disease progression

    by Lili Song, Rui Zhang, Liya Pan, Qiang Mi, Yi Yang, Xiang Wang, Yani Ma, Shuhong Shen, Benshang Li, Yanxin Li, et al.

    Relapse and disease progression are the primary causes of treatment failure and subsequent mortality in children with B‐cell acute lymphocytic leukemia (B‐ALL). At diagnosis and during treatment, dyslipidemia and the bone marrow adipose microenvironment are commonly observed in pediatric leukemia. However, the intricate connection between these factors and disease progression remains largely unexplored. We found that abnormal triglyceride accumulation increased the risk of death. Further investigation into the adipogenic potential of BM‐MSCs revealed a correlation between higher adipogenicity and elevated serum TG levels, which subsequently led to the rapid proliferation of leukemia cells and heightened the risk of post‐relapse mortality. Through RNA sequencing, Gremlin1 (GREM1) was identified as an important factor affecting adipogenicity. Silencing of GREM1 in BM‐MSCs induced adipogenic differentiation, partly through the BMP/SMAD signaling pathway. In an in vitro co‐culture model, shGREM1‐MSCs promoted B‐ALL cell proliferation and induced drug resistance to dexamethasone, while increasing sensitivity to L‐asparaginase. Furthermore, GREM1‐deficient BM‐MSCs promoted B‐ALL disease progression in xenograft models. This study provides new insights into overcoming drug resistance, relapse, and death by elucidating the novel mechanism by which GREM1 deficiency induces adipogenic differentiation of BM‐MSCs and promotes B‐ALL disease progression.


  • Open Access

    Impact of corticosteroids on the efficacy of CD19/22 CAR-T cell therapy in pediatric patients with B-ALL: a single-center study

    by Jing Yang, Jing Zhang, Xinyu Wan, Jiaoyang Cai, Tianyi Wang, Xiaomin Yang, Wenjie Li, Lixia Ding, Lili Song, Yan Miao, et al.

    Introduction: Corticosteroids are used for toxicity management, raising concerns about whether they may affect the anti-leukemic effects of chimeric antigen receptor (CAR)-T cells.Methods and results: In this study, we retrospectively analyzed patients (fined two subgroups based on disease burden. Of the 75 cases in the low disease burden (LDB) group (MRD < 5%, no extramedullary disease), there was no significant difference between the use of steroids and event-free survival (EFS) (p = 0.21) and overall survival (OS) (p = 0.26), and the same was found for the 119 cases in the high disease burden (HDB) group. After eliminating the effect of consolidative transplantation on the prognosis, the EFS of the patients who did not use steroids was better (p = 0.037) in the LDB group, but the difference was not significant in the HDB group. The median cumulative dexamethasone-equivalent dose was 0.56 mg/kg, and the EFS and OS were similar in the different cumulative dose groups. Furthermore, there was no difference in the recovery of B cells and the expansion of CAR-T cell copies.Conclusion and discussion: In conclusion, under the guidance of current CRS prevention and control measures, the rational use of corticosteroids does not affect the clinical efficacy and overall survival of CAR-T cell therapy in patients with B-ALL and also does not affect the persistence of CAR-T cells in vivo, but the dosage threshold needs further clinical or experimental verification.


  • Open Access

    Glycoprotein 350-targeted chimeric antigen receptor T-cell therapy for nonneoplastic chronic active Epstein-Barr virus infection: a case report

    by Yandi Liu, Jiaoyang Cai, Tianyi Wang, Jing Wang, Yanjing Tang, Xinyu Wan, Wenjie Li, Benshang Li, Qing Cao

    Background: Chronic active Epstein-Barr virus (CAEBV) infection is a rare disease in which the Epstein-Barr virus (EBV) persists and replicates, causing chronic symptoms and fatal complications. The treatment of CAEBV is still evolving. Our case report showed a new therapy for CAEBV. Case Description: A 14-year-old boy presented with a 10-month history of recurrent diarrhea, intermittent fever, abdominal pain, distension, dizziness, and fatigue. Physical examination findings included severe malnutrition and hepatosplenomegaly. The local hospital’s test results showed that the load of EBV DNA in peripheral blood was 5.99×106 copies/mL. Despite treatment with acyclovir, chemotherapy, and supportive care, the symptoms persisted. We determined the lymphocyte subtypes of EBV infection by fluorescence quantitative polymerase chain reaction and the expression of EBV envelope glycoprotein 350 (gp350) in peripheral blood lymphocytes. EBV not only infects B cells but also T and NK cells. According to the clinical manifestations, elevated EBV DNA levels, and positive EBV-encoded small RNA (EBER) status, the patient was diagnosed with CAEBV infection. The patient received a conditioning regimen of fludarabine and cyclophosphamide and an intravenous infusion of gp350-targeted chimeric antigen receptor T (CAR T) cells. After infusion, the patient developed grade I cytokine release syndrome (CRS) and was discharged 10 days later. During the follow-up, the EBV-DNA count remained undetectable. Conclusions: Our case report showed that CAR T-cell therapy is relatively safe and effective for treating CAEBV in children, with milder CRS compared to that in malignant tumors. However, a greater number of cases are needed to further evaluate the efficacy and safety.


  • Open Access

    Identification of early predictive biomarkers for severe cytokine release syndrome in pediatric patients with chimeric antigen receptor T-cell therapy

    by Meng Su, Luoquan Chen, Li Xie, Aurore Fleurie, Renaud Jonquieres, Qing Cao, Benshang Li, Ji Liang, Yanjing Tang

    CAR-T cell therapy is a revolutionary new treatment for hematological malignancies, but it can also result in significant adverse effects, with cytokine release syndrome (CRS) being the most common and potentially life-threatening. The identification of biomarkers to predict the severity of CRS is crucial to ensure the safety and efficacy of CAR-T therapy. To achieve this goal, we characterized the expression profiles of seven cytokines, four conventional biochemical markers, and five hematological markers prior to and following CAR-T cell infusion. Our results revealed that IL-2, IFN-γ, IL-6, and IL-10 are the key cytokines for predicting severe CRS (sCRS). Notably, IL-2 levels rise at an earlier stage of sCRS and have the potential to serve as the most effective cytokine for promptly detecting the condition’s onset. Furthermore, combining these cytokine biomarkers with hematological factors such as lymphocyte counts can further enhance their predictive performance. Finally, a predictive tree model including lymphocyte counts, IL-2, and IL-6 achieved an accuracy of 85.11% (95% CI = 0.763–0.916) for early prediction of sCRS. The model was validated in an independent cohort and achieved an accuracy of 74.47% (95% CI = 0.597–0.861). This new prediction model has the potential to become an effective tool for assessing the risk of CRS in clinical practice.


  • Histiocytic sarcoma following CAR T-cell therapy: a case report

    by Kang An, Yan He, Yanjing Tang, Xiaoyan Gu, Juan Qian, Benshang Li

    Background Development of secondary tumor after CART treatment is not well investigated. We report a pediatric B-cell acute lymphoblastic leukemia (B-ALL) patient who developed histiocytic sarcoma shortly after CART therapy. Case report: A 9-year-old boy diagnosed with relapsed B-ALL presenting the KRAS A146T mutation received autologous mouse-derived CD19 and CD22 chimeric antigen receptor T-cell therapy at our center (Chinese Clinical Trial Registry: ChiCTR2000032211). Thirty days post-CART therapy, the bone marrow showed complete remission. At 85 days post-CART therapy, the boy presented with fever and chills. An abdominal CT scan showed massive hepatomegaly with multiple low-density lesions in the liver. At 130 days post-CART therapy, a bone marrow smear showed abnormal proliferation of macrophages, some of which exhibited phagocytosis. On day 136 post-CART therapy, laparoscopic liver biopsy was performed, revealing multiple yellow–white lesions on the surface of the liver. Microscopically, multifocal lesions were observed, predominantly composed of cells with abundant cytoplasm. Immunohistochemical staining indicated histiocytic origin. Based on the immunohistochemical results, histiocytic sarcoma was diagnosed. The same cytogenetic markers were identified in histiocytic sarcoma. Conclusion: Our case illustrates a rare complication after CART therapy. The diagnosis and treatment of histiocytic sarcoma pose many challenges.